Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
The College of the Holy Cross is currently prosecuting a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio has 1 pending office action. This matter is handled by 1 distinct examiner and is located within 1 distinct art unit, reflecting a focused technical scope for the institution's current active filings at the USPTO.
The busiest examiner is HUI, SAN MING R, who is assigned 1 busiest examiner pending action. Because the portfolio only has 1 pending office action and 1 distinct examiner, HUI, SAN MING R is the sole examiner currently reviewing the college's active applications. This suggests that the institution's current efforts in the Biotechnology & Pharmaceuticals sector are concentrated on a single point of prosecution.
For practitioners, this profile indicates a streamlined interaction with the USPTO. With only 1 distinct art unit and 1 examiner involved, there is no need to coordinate across different technical groups. The resolution of the 1 pending office action by HUI, SAN MING R will be the primary factor in the portfolio's development within the Biotechnology & Pharmaceuticals field.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAJDA, KRISTIN ANN | 1 | 84.0% | +10.9% |
| CREWS, JARET JAMES | 1 | 44.7% | +70.3% |
| PATEL, OM | 1 | 58.6% | +54.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18540743 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | VAJDA, KRISTIN ANN | 72d |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18039107 | IMMUNOTHERAPY FOR CANCER | CREWS, JARET JAMES | 16d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17271541 | OPTICAL DEVICE AND METHOD | PATEL, OM | 114d overdue |
| 18039107 | IMMUNOTHERAPY FOR CANCER | CREWS, JARET JAMES | 16d |
| 18540743 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | VAJDA, KRISTIN ANN | 72d |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| 1691 | 1 |
| 3791 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18540743 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | VAJDA, KRISTIN ANN | 1622 | §102DPOther | Final Rejection | 72d | Pending | Dec 14, 2023 |
| 18039107 | IMMUNOTHERAPY FOR CANCER | CREWS, JARET JAMES | 1691 | §102§103 | Final Rejection | 16d | Pending | May 26, 2023 |
| 17271541 | OPTICAL DEVICE AND METHOD | PATEL, OM | 3791 | §103 | Non-Final OA | 114d overdue | Pending | Feb 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial